Insights & Publications
© 2018 Debevoise & Plimpton LLP
New Public and Private Efforts to Contain Healthcare Costs: What it Means for the Healthcare Industry
20 December 2017
View Client Update
As healthcare costs continue to climb, both public and private payors are pursuing strategies to expand access and contain costs.
The FDA and state governments have recently announced initiatives that are aimed at directly or indirectly reducing prescription drug costs.
Healthcare companies are using vertical integration as a means of controlling costs and developing new means of providing reasonably-priced, accessible healthcare.
These initiatives provide strategic opportunities for healthcare companies that can enhance the efficacy and cost-effectiveness of healthcare goods and services.
Mergers & Acquisitions
Andrew L. Bab
Jennifer L. Chu
Mark P. Goodman
Maura Kathleen Monaghan
View More Authors
UK and EU Agree in Principle to 21-Month Brexit Transition Period
U.S. Supreme Court Limits Enforcement of Terrorism-Related Judgments against Foreign Sovereigns
Private Equity Guide to Life Sciences Investing Under the Trump Administration: Food and Drug Administration (FDA) Developments
President Trump Bars Broadcom’s Proposed Takeover of Qualcomm
UK Modern Slavery Act Transparency Statement
Debevoise Women's Review